2023. Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s254. DOI:https://doi.org/10.25251/skin.7.supp.254.